Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
Withdrawn
This phase II trial studies how well carfilzomib and dexamethasone work in treating patients with multiple myeloma who previously underwent a stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as dexamethasone, may improve bone marrow function and increase blood cell counts. Giving carfilzomib together with dexamethasone may be an effective treatment for multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/15/2016
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Completed
This study is designed to evaluate the safety and to determine the maximum tolerated dose of carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple Myeloma patients who have not received treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2016
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Multiple Myeloma
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Completed
RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving thalidomide before and after peripheral stem cell transplant may be effective in treating newly diagnosed multiple myeloma. PURPO... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/26/2016
Locations: CCOP - Kansas City, Kansas City, Missouri
Conditions: Multiple Myeloma
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
Completed
The purpose of this study is to determine the ability of G-CSF to disrupt the bone marrow microenvironment as a means to increase the efficacy of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2016
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
Terminated
The purpose of this study is to evaluate the effect of dexamethasone intravitreal implant (Ozurdex) in combination with pars plana vitrectomy and membrane peeling for idiopathic epiretinal membrane (ERM).
Gender:
ALL
Ages:
All
Trial Updated:
07/26/2016
Locations: St. Lukes Hospital, Chesterfield, Missouri +2 locations
Conditions: Epiretinal Membrane, Macular Edema
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
Completed
RATIONALE: Gabapentin may prevent or reduce delayed nausea and vomiting caused by chemotherapy. It is not yet known whether gabapentin is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase III trial is studying the side effects of gabapentin and to see how well it works compared with a placebo in preventing nausea and vomiting in patients receiving chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2016
Locations: Missouri Baptist Cancer Center, Saint Louis, Missouri +2 locations
Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and alternating regimens of chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
06/30/2016
Locations: Ellis Fischel Cancer Center - Columbia, Columbia, Missouri +1 locations
Conditions: Leukemia, Lymphoma
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Completed
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2016
Locations: Lifelong Vision Foundation, Chesterfield, Missouri
Conditions: Macular Edema
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Completed
The hypothesis is that the substitution of multi-day oral aprepitant with (intravenous) IV fosaprepitant, in combination with a 5-HT3 receptor antagonists (5HT3RA) + dexamethasone will provide comparable protection from 5 day cisplatin chemotherapy induced nausea and vomiting, compared to the results of our prior study of aprepitant. This study will be the first clinical trial evaluating fosaprepitant in patients receiving multi-day cisplatin. This will be a single arm, phase II study. The inves... Read More
Gender:
MALE
Ages:
15 years and above
Trial Updated:
04/18/2016
Locations: Siteman Cancer Center, St. Louis, Missouri
Conditions: Chemotherapy-Induced Nausea and Vomiting
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Completed
The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory multiple myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2016
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Multiple Myeloma
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
02/19/2016
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Leukemia
Blood and Marrow Transplant Clinical Research Network
Completed
The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
02/17/2016
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Bone Marrow Transplantation, Blood Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Graft vs Host Disease